BriaCell Therapeutics Corp Net Income
| BCTXZ Stock | 0.14 0 3.43% |
As of the 11th of February 2026, BriaCell Therapeutics shows the Mean Deviation of 9.21, standard deviation of 12.44, and Risk Adjusted Performance of (0.05). BriaCell Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
BriaCell Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BriaCell Therapeutics' valuation are provided below:We have found one hundred twenty available fundamental signals for BriaCell Therapeutics Corp, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BriaCell Therapeutics Corp prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 4.7 M in 2026. Enterprise Value is likely to rise to about (6.8 M) in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -23.9 M | -22.7 M | |
| Net Loss | -5.7 M | -6 M | |
| Net Loss | (77.63) | (81.51) | |
| Net Income Per E B T | 1.14 | 1.08 |
BriaCell | Net Income | Build AI portfolio with BriaCell Stock |
The evolution of Net Income for BriaCell Therapeutics Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how BriaCell Therapeutics compares to historical norms and industry peers.
Latest BriaCell Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of BriaCell Therapeutics Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in BriaCell Therapeutics financial statement analysis. It represents the amount of money remaining after all of BriaCell Therapeutics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is BriaCell Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BriaCell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (26.56 M) | 10 Years Trend |
|
Net Income |
| Timeline |
BriaCell Net Income Regression Statistics
| Arithmetic Mean | (8,892,757) | |
| Geometric Mean | 1,057,509 | |
| Coefficient Of Variation | (145.90) | |
| Mean Deviation | 10,348,634 | |
| Median | (2,584,122) | |
| Standard Deviation | 12,974,600 | |
| Sample Variance | 168.3T | |
| Range | 37.9M | |
| R-Value | (0.71) | |
| Mean Square Error | 89.1T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (1,824,101) | |
| Total Sum of Squares | 2693.4T |
BriaCell Net Income History
Other Fundumenentals of BriaCell Therapeutics
BriaCell Therapeutics Net Income component correlations
BriaCell Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for BriaCell Therapeutics is extremely important. It helps to project a fair market value of BriaCell Stock properly, considering its historical fundamentals such as Net Income. Since BriaCell Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BriaCell Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BriaCell Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BriaCell Therapeutics. Projected growth potential of BriaCell fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive BriaCell Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of BriaCell Therapeutics is measured differently than its book value, which is the value of BriaCell that is recorded on the company's balance sheet. Investors also form their own opinion of BriaCell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BriaCell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BriaCell Therapeutics' market value can be influenced by many factors that don't directly affect BriaCell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BriaCell Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BriaCell Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BriaCell Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
BriaCell Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BriaCell Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BriaCell Therapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in BriaCell Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding BriaCell Therapeutics Corp or generate 0.0% return on investment in BriaCell Therapeutics over 90 days. BriaCell Therapeutics is related to or competes with NewcelX, XORTX Therapeutics, Elevai Labs, Virax Biolabs, Ainos, Dermata Therapeutics, and Avenue Therapeutics. BriaCell Therapeutics is entity of United States More
BriaCell Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BriaCell Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BriaCell Therapeutics Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 69.68 | |||
| Value At Risk | (22.22) | |||
| Potential Upside | 18.52 |
BriaCell Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BriaCell Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BriaCell Therapeutics' standard deviation. In reality, there are many statistical measures that can use BriaCell Therapeutics historical prices to predict the future BriaCell Therapeutics' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.80) | |||
| Total Risk Alpha | (2.19) | |||
| Treynor Ratio | 0.7113 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BriaCell Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
BriaCell Therapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | 0.7213 | |||
| Mean Deviation | 9.21 | |||
| Coefficient Of Variation | (1,388) | |||
| Standard Deviation | 12.44 | |||
| Variance | 154.74 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.80) | |||
| Total Risk Alpha | (2.19) | |||
| Treynor Ratio | 0.7113 | |||
| Maximum Drawdown | 69.68 | |||
| Value At Risk | (22.22) | |||
| Potential Upside | 18.52 | |||
| Skewness | (0.44) | |||
| Kurtosis | 1.3 |
BriaCell Therapeutics Backtested Returns
BriaCell Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0607, which signifies that the company had a -0.0607 % return per unit of risk over the last 3 months. BriaCell Therapeutics Corp exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BriaCell Therapeutics' Mean Deviation of 9.21, risk adjusted performance of (0.05), and Standard Deviation of 12.44 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -1.27, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning BriaCell Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, BriaCell Therapeutics is expected to outperform it. At this point, BriaCell Therapeutics has a negative expected return of -0.82%. Please make sure to confirm BriaCell Therapeutics' information ratio, kurtosis, period momentum indicator, as well as the relationship between the treynor ratio and day median price , to decide if BriaCell Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.54 |
Good reverse predictability
BriaCell Therapeutics Corp has good reverse predictability. Overlapping area represents the amount of predictability between BriaCell Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BriaCell Therapeutics price movement. The serial correlation of -0.54 indicates that about 54.0% of current BriaCell Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.54 | |
| Spearman Rank Test | -0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
BriaCell Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, BriaCell Therapeutics Corp reported net income of (26.56 Million). This is 107.78% lower than that of the Healthcare sector and 137.91% lower than that of the Biotechnology industry. The net income for all United States stocks is 104.65% higher than that of the company.
BriaCell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BriaCell Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BriaCell Therapeutics could also be used in its relative valuation, which is a method of valuing BriaCell Therapeutics by comparing valuation metrics of similar companies.BriaCell Therapeutics is currently under evaluation in net income category among its peers.
BriaCell Fundamentals
| EBITDA | (36.63 M) | |||
| Net Income | (26.56 M) | |||
| Total Debt | 4.32 M | |||
| Cash Flow From Operations | (28.17 M) | |||
| Total Asset | 21.65 M | |||
| Retained Earnings | (154.51 M) | |||
| Working Capital | (3.81 M) | |||
| Net Asset | 21.65 M |
About BriaCell Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BriaCell Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BriaCell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BriaCell Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BriaCell Stock Analysis
When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.